TCGA-77-A5GF-01A-21R-A27Q-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.450
- G2M_CHECKPOINT+0.440
- HEDGEHOG_SIGNALING+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MTORC1_SIGNALING+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- MITOTIC_SPINDLE+0.180
- DNA_REPAIR+0.160
Top 10 suppressed
- COAGULATION-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.340
- ALLOGRAFT_REJECTION-0.330
- KRAS_SIGNALING_UP-0.330
- TGF_BETA_SIGNALING-0.330
- COMPLEMENT-0.310
- ANGIOGENESIS-0.300
- ANDROGEN_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.872 |
| 2 | TCGA-96-A4JK-01A-11R-A24Z-07 | — | cohortSQ2 | 0.869 |
| 3 | TCGA-O2-A52S-01A-11R-A262-07 | — | cohortSQ2 | 0.867 |
| 4 | TCGA-63-7023-01A-11R-1949-07 | — | cohortSQ2 | 0.862 |
| 5 | TCGA-77-7139-01A-11R-2045-07 | — | cohortSQ2 | 0.858 |
| 6 | TCGA-NC-A5HN-01A-11R-A26W-07 | — | cohortSQ2 | 0.858 |
| 7 | MNG531 | — | — | 0.858 |
| 8 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.854 |
| 9 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.854 |
| 10 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |